Lincoln Pharmaceuticals is currently trading at Rs 29.95, up by 1.55 points or 5.46% from its previous closing of Rs 28.40 on the BSE.
The scrip opened at Rs. 29.95 and has touched a high and low of Rs 29.95 and Rs 29.95 respectively.
The BSE group 'B' stock of face value Rs 10 has touched a 52 week high of Rs 47.00 on 20-Jan-2011 and a 52 week low of Rs 19.25 on 16-Dec-2011.
Last one week high and low of the scrip stood at Rs 31.90 and Rs 24.30 respectively. The current market cap of the company is Rs 48.85 crore.
The promoters holding in the company stood at 24.54% while Non-Institutions held 75.46% stake in the company.
Lincoln Pharmaceuticals (LPL), a world class pharmaceutical company has entered into an agreement with Switzerland-based Phafag AG, for its Caroverine molecule for the treatment of Tinnitus-commonly known as “ringing in the ear”, a condition where inner hair cells get damaged causing continuous depression, anxiety and insomnia in patients. Millions of people around the world suffer from Tinnitus. It becomes the first company in India to introduce a cure for Tinnitus as Tinnex injection using Caroverine.
With a large number of people suffering from Tinnitus and not much is being done about it, the company invested in the R&D and took the first steps towards bringing the patients suffering from Tinnitus closer to treatment. The company developed Caroverine injection under research and development collaboration with Phafag AG to introduce Tinnex.
Tinnex Injection is a slow intravenous infusion. The dosage differs from patient to patient and depends on the severity.
Lincoln Pharmaceuticals has its own manufacturing facilities, covering all the major dosage forms, like tablets, capsules, injectables, syrups, Ointments, etc. Its present manufacturing activities are located near Ahmedabad. The plant spreads across 30,000 square meters.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1797.80 |
| Dr. Reddys Lab | 1213.90 |
| Cipla | 1486.30 |
| Lupin | 2069.95 |
| Zydus Lifesciences | 948.70 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
Become a savvy and confident
stock investor.
Don't miss out! First 10 users today get it FREE
Download APP
